PAULA QUATTLEBAUM: Open Payments
NPI 1487376935 · MALVERN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$272 in 13 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $99 · 2025 $272
Food & beverage: $272
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 4 | $68 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: INGREZZA, FANAPT, Auvelity, ABILIFY MAINTENA, TRINTELLIX, REXULTI, CAPLYTA, HETLIOZ.
Industry payments across AR — which companies pay providers there.
